CPT1A and prostate carcinoma: Treatment with luminespib (NVP-AUY922), a second-generation heat shock protein 90 (HSP90) inhibitor, increased the abundance of proteins involved in OXPHOS and fatty acid metabolism in prostate cancer patient-derived explants, and increased mitochondrial mass and expression of genes associated with fatty acid metabolism processes, including CPT1A, in prostate cancer cell lines [44].